The present stud is a dose effect study designed to test for the safety and efficacy of E1-deleted recombinant adenovirus containing the CFTR cDNA under a CMV-beta actin promoter in CF nasal epithelia. Three patients will be selected for each dose. The goal is to define the safety and efficacy of the various doses as a function of time, with the ultimate goal of using these studies to understand safety, efficacy, and potential dosing intervals pertinent to this novel of therapy.
Showing the most recent 10 out of 782 publications